Heart rate adjustment of PR interval in middle-aged and older adults

Journal of Electrocardiology

Volumn 45, Issue 1, 2012, Pages 66-69

  Soliman, Elsayed Z ^a   Rautaharju, Pentti M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

First degree AV block; Heart rate; PR interval; QT interval

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; ELECTROCARDIOGRAM; EVALUATION; FEMALE; HEART RATE; HUMAN; MALE; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; RACE; SEX;

ADULT; AGED; AGED, 80 AND OVER; ATRIOVENTRICULAR NODE; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PREDICTIVE VALUE OF TESTS; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 84855337786     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2011.06.003     Document Type: Article

References (17)

1. Soliman EZ, Prineas RJ, Case LD, Zhang ZM, Goff Jr DC. Ethnic distribution of electrocardiographic predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities Study (ARIC). Stroke 2009;40:1204.
2. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for a trial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739.
3. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009;301:2571.
4. U.S. Food and Drug Administration. Labeling changes for Kaletra reflecting new QT/QTC interval and PR interval prolongation information. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ hivandaidsactivities/ucm155697.htm [Accessed on 12 April 2011].
5. U.S. Food and Drug Administration. Invirase (saquinavir): ongoing safety review of clinical trial data. http://www.fda.gov/Safety/ MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ ucm201563.htm [accessed on 12 April 2011].
6. Soliman EZ, Lundgren JD, Roediger MP, et al. Associations between ritonavir boosted protease inhibitors with QTc and PR interval durations in the Strategies for Management of Antiretroviral Therapy (SMART) trial. AIDS 2011;25:367.
7. Pfeufer A, van Noord C, Marciante KD, et al. Genome-wide association study of PR interval. Nat Genet 2010;42:153.
8. Smith JG, Magnani JW, Palmer C, et al. Genome-wide association studies of the PR interval in African Americans. PLoS Genet 2011;7: e1001304.
9. Atterhog JH, Loogna E. PR interval in relation to heart rate during exercise and the influence of posture and autonomic tone. J Electrocardiol 1977;10:331.
10. Danter WR, Carruthers SG. The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function. Br J Clin Pharmacol 1990;30:490.
11. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1994;32:1.
12. Rautaharju P, Rautaharju F. Investigative electrocardiography in epidemiological studies and clinical trials. London: Springer-Verlag London Limited; 2007.
13. Rautaharju PM, Zhang ZM, Prineas R, Heiss G. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 2004;93:1017.
14. Rautaharju PM, Calhoun HP, Chaitman BR. NOVACODE serial ECG classification system for clinical trials and epidemiological studies. J Electrocardiol 1992;24:179.
15. Rautaharju PM, MacInnis PJ, Warren JW, Wolf HK, Rykers PM, Calhoun HP. Methodology of ECG interpretation in the Dalhousie Program. NOVACODE ECG classification procedures for clinical trials and population health surveys. Methods Inf Med 1990;29:362.
16. Katz AM. Cardiac ionic channels. N Engl J Med 1993;328:1244.
17. Issa ZF, Miller JM, Zipes DP, editors. A Clinical arrhythmology and electrophysiology: a companion to Braunwald's heart disease. Philadelphia: Saunders Elsevier; 2008. p. 130.